AC10001 is a leading biotechnology company developing new class of innovative medicines based on breakthrough discovery in molecular biology. The company is committed to anti-tumor bispecific antibody development. The lead asset is an innovative humanized bispecific antibody for the treatment of malignant ascites. Its phase II study is in preparation, and phase I study shows excellent ascites control and clearance efficacy.
The detailed information can be found in the following figures.
Figure 1: AC10001
Figure 2: AC10001 -3
ACCESS CHINA Asset transaction platform coming soon!
Hundreds of assets are available for out-licensing.
About ACCESS CHINA
ACCESS CHINA is the most effective deal-making platform for pharma and biotech leaders looking to enter/expand in the China market. We provide direct opportunities connecting the right partners for development, licensing, financing and commercial collaborations.